课题基金 / 基金详情

I 131 ANTI B1 ANTIBODY IN NON HODGKINS LYMPHOMA VS UNLABELED ANTI B1

I 131 ANTI B1 ANTIBODY IN NON HODGKINS LYMPHOMA VS UNLABELED ANTI B1
非霍奇金淋巴瘤中的 I 131 抗 B1 抗体与未标记抗 B1 抗体
批准号：
6297035
负责人：
MARK S. KAMINSKI
金额：
$0.02万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6297035
关键词：
antiantibody clinical research human subject human therapy evaluation iodine longitudinal human study neoplasm /cancer immunotherapy neoplasm /cancer radionuclide therapy nonHodgkin's lymphoma

项目摘要

项目成果

MARK S. KAMINSKI的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项随机、双组、开放标签、多中心的研究，比较了碘-131抗b1抗体与未标记抗b1抗体治疗化疗难治性低级别b细胞非霍奇金淋巴瘤（NHL）的安全性和有效性。78名患者将随机接受碘-131抗b1抗体（A组）或未标记的抗b1抗体（B组）。随机接受未标记的抗b1抗体的患者在淋巴瘤进展后可能交叉接受放射性标记的碘-131抗b1抗体。两组的反应将分别在6周、3个月和2年内每隔3个月进行评估。
英文摘要
This is a randomized, two-arm, open-label, multicenter, study comparing the safety and efficacy of Iodine-131 Anti-B1 Antibody to unlabeled Anti-B1 Antibody for the treatment of chemotherapy-refractory low-grade B-cell non-Hodgkin's lymphoma (NHL). Seventy-eight patients will be randomized to receive iodine-131 Anti-B1 Antibody (Arm A) or unlabeled Anti-B1 Antibody (Arm B). Patients randomized to receive unlabeled Anti-B1 Antibody may crossover and receive radiolabeled Iodine-131 Anti-B1 Antibody following progression of their lymphoma. Response in both arms will be assessed at 6 weeks, 3 months, and then at 3-monthly intervals for two years.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RETREATMENT OF NON HODGKINS LYMPHOMA W/ IODINE 131 ANTI B1 ANTIBODY
I 131 ANTI B1 ANTIBODY IN NON HODGKINS LYMPHOMA VS UNLABELED ANTI B1
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
(131) IODINE-B1 RADIOIMMUNOTHERAPY OF ADVANCED NONHODGKIN'S LYMPHOMA
海外基金